Peptide News Digest

ADA 2026 Day 3: CagriSema REIMAGINE 1/2/3 Lancet Publication, Mazdutide GLORY-2 + DREAMS-3 Beats Semaglutide, Novo Zenagamtide 14.6%, Elecoglipron China Phase 1b, MetaVia + Lexicon

ADA Day 3: REIMAGINE 1/2/3 publishes in Lancet, mazdutide beats semaglutide head-to-head, zenagamtide hits 14.6% in T2D, elecoglipron and MetaVia add detail.

8 stories · Covering clinical-trials, industry

Editor's Note

Sunday belonged to the amylin and oral-peptide threads that have been building all week. Novo Nordisk dropped the full Phase 3 REIMAGINE 1/2/3 set, with simultaneous Lancet publication, including the head-to-head readout where CagriSema beat semaglutide alone in type 2 diabetes (14.2% versus 10.2% weight loss; 1.91 versus 1.75 percent A1C drop). Its amylin/GLP-1 single molecule zenagamtide, the artist formerly known as amycretin, posted 14.6% weight loss and a 1.71-point A1C drop in a Phase 2 T2D study with 89% reaching A1C under 7%, clearing the way for a Phase 3 program in the second half of the year. The Chinese pipeline kept advancing alongside, with Innovent's mazdutide hitting 20.1% weight loss in GLORY-2 and beating semaglutide in DREAMS-3, AstraZeneca's elecoglipron adding China Phase 1b detail, and MetaVia's higher-dose DA-1726 cohort filling out the dual GLP-1/glucagon story. Lexicon's sotagliflozin and pilavapadin posters held the day's small non-incretin corner.

Clinical Trials

Novo Nordisk's CagriSema REIMAGINE 1/2/3 Phase 3 Data Lands With Simultaneous Lancet Publication: 14.2% Weight Loss and 1.91% HbA1c Drop in Type 2 Diabetes, Beating Semaglutide Alone

Novo Nordisk presented the full REIMAGINE 1/2/3 Phase 3 program in a Sunday symposium at ADA 2026, with simultaneous publication in The Lancet Diabetes & Endocrinology (REIMAGINE 1 and 2) and The Lancet (REIMAGINE 3). REIMAGINE 2 (n=2,713; 68 weeks) showed CagriSema 2.4/2.4 mg producing 14.2% weight loss and 1.91% HbA1c reduction versus 10.2% and 1.75% for semaglutide 2.4 mg alone. REIMAGINE 1 (n=189; 40 weeks) showed 13.8% weight loss and 1.8% HbA1c drop vs placebo. REIMAGINE 3 (n=274) showed 12.0% weight loss and a 2.33% HbA1c drop when added to basal insulin.

#novo-nordisk #cagrisema #reimagine-2 #reimagine-3 #lancet #type-2-diabetes #ada-2026
Clinical Trials

Novo Nordisk Zenagamtide Phase 2 in Type 2 Diabetes: 1.71% HbA1c Drop and 14.6% Weight Loss at 40 mg, 89% Reaching HbA1c Under 7%; Phase 3 Slated for H2 2026

Novo Nordisk presented Phase 2 data for zenagamtide (formerly amycretin), its unimolecular GLP-1 and amylin receptor agonist, at ADA 2026 in 262 adults with type 2 diabetes randomized across six subcutaneous doses (0.4 to 40 mg) versus placebo. The 40 mg arm cut HbA1c by 1.71 percentage points and reduced body weight by 14.6% at 36 weeks, with nearly 89% of patients reaching HbA1c below 7%. The study met its primary HbA1c endpoint across all doses; Novo plans Phase 3 in H2 2026 and hosted a same-day R&D investor event.

#novo-nordisk #zenagamtide #amycretin #amylin #glp-1 #phase-2 #ada-2026
Clinical Trials

Innovent Mazdutide GLORY-2 Phase 3: 20.1% Weight Loss at 9 mg in Chinese Adults With Obesity

At ADA 2026 on Sunday June 7, Innovent presented the Phase 3 GLORY-2 trial of mazdutide 9 mg in Chinese adults with obesity, presented by Leili Gao of Peking University People's Hospital. The dual GLP-1/glucagon agonist drove up to 20.1% mean weight loss and met its primary endpoint and all key secondary endpoints. The result extends China's homegrown obesity-peptide leadership, with mazdutide already approved by China's NMPA in 2025.

#innovent #mazdutide #glory-2 #glp-1-glucagon #obesity #china #ada-2026
Clinical Trials

Innovent Mazdutide DREAMS-3 Head-to-Head Beats Semaglutide in Chinese Type 2 Diabetes: 48% Hit A1C Under 7% Plus 10% Weight Loss Versus 21% on Semaglutide

Innovent's DREAMS-3 Phase 3b head-to-head trial of mazdutide versus semaglutide in Chinese adults with type 2 diabetes and obesity was presented Sunday June 7 by Linong Ji of Peking University People's Hospital. On the composite primary endpoint, 48.0% of mazdutide-treated patients reached HbA1c under 7% plus at least 10% body weight reduction versus 21.0% on semaglutide. The readout is the first Phase 3 head-to-head defeat for semaglutide outside Lilly's tirzepatide series.

#innovent #mazdutide #dreams-3 #semaglutide #head-to-head #type-2-diabetes #ada-2026
Clinical Trials

AstraZeneca Elecoglipron Adds China Phase 1b Detail at ADA 2026; VISTA and SOLSTICE Phase 2b Symposium Set for Monday

Eccogene and AstraZeneca presented a Sunday June 7 poster on the safety, tolerability, and PK/PD of elecoglipron (AZD5004/ECC5004) in Chinese adults with obesity or overweight, with or without type 2 diabetes. The Monday June 8 symposium covers the VISTA Phase 2b obesity readout and the SOLSTICE Phase 2b trial in type 2 diabetes, where the oral GLP-1 reduced HbA1c at 26 weeks and supported a Phase 3 transition. AstraZeneca plans to develop elecoglipron as an oral combination backbone alongside dapagliflozin in diabetes/CKD/HF and AZD0780 in dyslipidemia.

#astrazeneca #eccogene #elecoglipron #azd5004 #oral-glp-1 #vista #solstice #ada-2026
Clinical Trials

MetaVia DA-1726 Higher-Dose Phase 1 Cohort Poster at ADA 2026, Plus Vanoglipel Combinations in MASH and Diabetes

MetaVia presented three Sunday June 7 posters at ADA 2026. The Phase 1 higher-dose cohort of DA-1726, the once-weekly dual GLP-1/glucagon oxyntomodulin analog, builds on the prior 32 mg multiple-ascending-dose readout that showed strong effects on weight, glucose, and waist. The GPR119 agonist vanoglipel was presented in two combinations: with resmetirom for synergistic hepatoprotective effects in MASH, and with metformin for joint glycemic and weight benefit.

#metavia #da-1726 #vanoglipel #gpr119 #mash #ada-2026
Clinical Trials

Lexicon Sotagliflozin and Pilavapadin Posters at ADA 2026: Type 1 Diabetes Subgroup Consistency and Phase 1 Renal-Function PK

Lexicon Pharmaceuticals presented two Sunday June 7 posters at ADA 2026. The pooled inTandem analysis of sotagliflozin, a dual SGLT-1/SGLT-2 inhibitor, showed consistent glycemic improvement and HbA1c reductions across key adult type 1 diabetes subgroups (M. Belinda Hardin). A separate Phase 1 study of the non-opioid pain candidate pilavapadin showed renal function did not affect its pharmacokinetics in patients with diabetic peripheral neuropathic pain (Rodica Pop-Busui).

#lexicon-pharmaceuticals #sotagliflozin #type-1-diabetes #pilavapadin #diabetic-neuropathic-pain #ada-2026
Industry

Novo Nordisk R&D Investor Event at ADA 2026: Pipeline Strategy After the CagriSema and Zenagamtide Day

Novo Nordisk hosted its R&D investor event in New Orleans on Sunday June 7, the same day as the CagriSema and zenagamtide readouts. The pipeline conversation centered on the combination strategy that pairs CagriSema and zenagamtide with the Wegovy injection and Wegovy pill, plus IcoSema and the FGF21 analog efruxifermin in MASH. Across 40 ADA abstracts, the company is reframing itself from a single-product GLP-1 leader to a multi-mechanism cardiometabolic pipeline.

#novo-nordisk #ada-2026 #pipeline #cagrisema #zenagamtide #efruxifermin